
Effectiveness Clinically Approved
The latest study which included 25 patients with severe pulmonary valve regurgitation (in the native RVOT) showed 100% success rate and good mid-term effectiveness without device-related serious adverse events.
The latest study which included 25 patients with severe pulmonary valve regurgitation (in the native RVOT) showed 100% success rate and good mid-term effectiveness without device-related serious adverse events.
Pressure between the RV and the PA before and after PULSTA™ implantation shows that even after 4 years of implantation, the PULSTA™ is safe and stable in its performance.
NYHA functional class of patients improved to class I in
all patients after PULSTA™ implantation.
The New York Heart Association (NYHA) functional class